Liver vessel enhancement by gd-bopta and gd-eob-dtpa: a comparison in healthy volunteers

Brismar, Torkel B.; Dahlström, Nils; Edsborg, Nick; Persson, Anders; Smedby, Örjan; Albiin, Nils

doi:10.1080/02841850903055603

Cited by 72 publications

(69 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to a recent study that directly compared the diagnostic performance of two contrast agents on the same patients, when focusing on the diagnosis of FNH, Gd-BOPTA is superior to Gd-EOB-DTPA due to significantly higher lesion contrast ratios in the arterial and late venous phases [12]. Indeed, the arterial enhancement of vessels and lesions in Gd-EOB-DTPA-enhanced MRI is lower than that in Gd-BOPTA-enhanced MRI [37]. However, Gd-EOB-DTPA has HBP occurring faster than it does in Gd-BOPTA (10-30 minutes versus 60-120 minutes after injection of contrast agents), making Gd-EOB-DTPA more convenient to use [12].…”

Section: Discussionmentioning

confidence: 96%

The diagnostic value of Gd-EOB-DTPA-MRI for the diagnosis of focal nodular hyperplasia: a systematic review and meta-analysis

Suh

Kim

et al. 2014

Eur Radiol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 96%

The diagnostic value of Gd-EOB-DTPA-MRI for the diagnosis of focal nodular hyperplasia: a systematic review and meta-analysis

Suh

Kim

et al. 2014

Eur Radiol

View full text Add to dashboard Cite

show abstract

“…When compared to Gd-BOPTA, at standard doses Gd-EOB-DTPA demonstrates lower enhancement in normal vasculature and solid abdominal organs [9] and lower dynamic enhancement of the liver vasculature [10]. Frydrychowicz et al compared dynamic post contrast hepatic vasculature signal to noise ratio (SNR) with the higher (non-FDA approved) Gd-EOB-DTPA dose of 0.05 mmol/kg to the standard dose of Gd-BOPTA.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Dynamic Phase Enhancement of Hepatocellular Carcinoma Using Gadoxetate Disodium vs Gadobenate Dimeglumine

Tirkes

Mehta

Aisen

et al. 2015

Journal of Computer Assisted Tomography

View full text Add to dashboard Cite

PURPOSETo determine the differences in enhancement pattern of hepatocellular carcinoma (HCC) during first 5 minutes of post-contrast phases MRI with gadoxetic acid (Gd-EOB-DTPA) versus gadobenate dimeglumine (Gd-BOPTA) using the FDA approved doses. METHODS AND MATERIALS95 patients with HCC were examined on 1.5 T scanner; 74 patients with Gd-BOPTA and 21 with Gd-EOB-DTPA. Using the same MRI parameters, post-contrast imaging was performed at pre-contrast, arterial, portal venous, equilibrium, and 5 minute delayed phases. Gd-EOB-DTPA was administered at a dose of 0.025 mmol/kg body weight and Gd-BOPTA at a dose of 0.1 mmol/kg body weight. Both agents were injected at rate of 2 mL/sec and arterial phase was timed by using bolus-triggering software. The contrast-tonoise ratio (CNR) was calculated by (SI lesion -SI liver )/SD background . (SD=Standard Deviation, SI=signal intensity) RESULTSMean CNRs were not statistically significant different in arterial (p=0.3), portal venous (p=0

show abstract

“…The smaller volume shortens the duration of arterial enhancement and reduces signal intensity [21]. Therefore, some institutions use higher doses of 0.05 mmol/kg [18,22,23]. Other institutions use a fixed dose of 10 ml equaling the package size, resulting in varying concentrations of gadoxetate disodium, depending on the patient's body weight [6, 8 -10, 12, 14].…”

Section: Influence Of Contrast Dosementioning

confidence: 99%

Transient Severe Respiratory Motion Artifacts After Application of Gadoxetate Disodium: What We Currently Know

Well

Weinrich

Adam

et al. 2017

Fortschr Röntgenstr

View full text Add to dashboard Cite

Background Gadoxetate disodium is an intracellular contrast agent for magnetic resonance imaging (MRI) of the liver. Recent publications revealed that injection of gadoxetate disodium can lead to imaging artifacts due to transient severe motion (TSM) in the arterial phase of contrast-enhanced liver MRI. In this review we present and discuss published frequencies of TSM, contrast injection and image acquisition protocols, potential risk factors, and proposed strategies to avoid or minimize the effects of TSM. Method Two reviewers independently searched the PubMed search engine for “transient severe motion artifact” and related terms. Reference lists of retrieved articles were also searched. The two reviewers selected in consensus nine studies that reported both frequencies of TSM and potential risk factors. Study data were extracted by both reviewers, and disagreement was resolved by consensus. Results and Conclusion TSM is caused by impaired breath-hold ability after gadoxetate disodium injection and occurs in 5 – 22 % of patients. The dose of applied contrast agent, repeated exposure to gadoxetate disodium, high BMI and pulmonary disease have been described as potential risk factors for TSM. However, there are only few concordant results on this topic and the pathophysiology of TSM has not been identified. Proposed strategies for the prevention of TSM are slow injection rates and low doses of diluted gadoxetate disodium. Accelerated and free-breathing MRI sequence protocols and breath-hold training may minimize the effects of TSM. Further prospective studies are needed to confirm these strategies and to identify the underlying mechanism of TSM. Key Points Citation Format

show abstract

Liver vessel enhancement by gd-bopta and gd-eob-dtpa: a comparison in healthy volunteers

Cited by 72 publications

References 14 publications

The diagnostic value of Gd-EOB-DTPA-MRI for the diagnosis of focal nodular hyperplasia: a systematic review and meta-analysis

The diagnostic value of Gd-EOB-DTPA-MRI for the diagnosis of focal nodular hyperplasia: a systematic review and meta-analysis

Comparison of Dynamic Phase Enhancement of Hepatocellular Carcinoma Using Gadoxetate Disodium vs Gadobenate Dimeglumine

Transient Severe Respiratory Motion Artifacts After Application of Gadoxetate Disodium: What We Currently Know

Contact Info

Product

Resources

About